Gefitinib [USAN] en es it fr

Gefitinib [USAN] Brand names, Gefitinib [USAN] Analogs

Gefitinib [USAN] Brand Names Mixture

  • No information avaliable

Gefitinib [USAN] Chemical_Formula


Gefitinib [USAN] RX_link

Gefitinib [USAN] fda sheet

Gefitinib_[USAN] FDA

Gefitinib [USAN] msds (material safety sheet)

Gefitinib_[USAN] MSDS

Gefitinib [USAN] Synthesis Reference

No information avaliable

Gefitinib [USAN] Molecular Weight

446.902 g/mol

Gefitinib [USAN] Melting Point

No information avaliable

Gefitinib [USAN] H2O Solubility

Sparingly soluble (<pH4)

Gefitinib [USAN] State


Gefitinib [USAN] LogP


Gefitinib [USAN] Dosage Forms


Gefitinib [USAN] Indication

For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Gefitinib [USAN] Pharmacology

Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.

Gefitinib [USAN] Absorption

Absorbed slowly after oral administration with mean bioavailability of 60%.

Gefitinib [USAN] side effects and Toxicity

No information avaliable

Gefitinib [USAN] Patient Information

Gefitinib [USAN] Organisms Affected

Humans and other mammals